Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Molecular targets of FTY720 (fingolimod).
Animal Models in Neurology: Drawbacks and Opportunities.
Comprehending the inexplicable: qualitative accounts of black Caribbean and white british people severely affected by multiple sclerosis.
Modulation of Sox10, HIF-1α, Survivin, and YAP by Minocycline in the Treatment of Neurodevelopmental Handicaps following Hypoxic Insult.
Early activation of CD4+ and CD8+ T lymphocytes by myelin basic protein in subjects with MS.
Transcriptomics: mRNA and alternative splicing.
The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan
Medical marijuana: clearing away the smoke.
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
In vitro Biological Characterization of IFN-β-1a major Glycoforms.
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial.
Don't stress about it!: Is stress management a disease-modifying therapy for multiple sclerosis?
[Epidemiology of multiple sclerosis in the Primosky Krai and Far East regions.]
In vitro modeling of central nervous system myelination and remyelination.
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
Vivitrol dosing and administration

Pages